{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:22:27Z","timestamp":1787714547394,"version":"build-2784847793"},"reference-count":13,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Transgender Health"],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To analyze the effectiveness of gonadotropin-releasing hormone agonists (GnRHa) in suppressing the hypothalamic-pituitary gonadal (HPG) axis in transgender adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective review of electronic medical records of transgender youth and children with central precocious puberty (CPP) treated with GnRHa. Blood levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, and\/or estradiol at baseline and during treatment were compared between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Data from 30 transgender and 30 patients with CPP were analyzed. Transgender patients were older with a mean age of 13.0\u00b12.1 years versus 7.7\u00b12.3 years in the CPP group,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;0.001. There were more patients assigned male at birth (AMAB) in the transgender group (56.7%) than males in the CPP group (30%),\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;0.001. The transgender group had more patients with advanced puberty with 56% of patients having a Tanner stage of IV\u2013V, versus none in the CPP group,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;0.01. GnRHa treatment resulted in LH, FSH, and testosterone levels that were similar in males with CPP versus transgender patients AMAB; suppression of LH and FSH levels was similar in females with CPP versus transgender patients assigned female at birth, but estradiol levels were higher in the latter (1.8\u00b11.8\u2009pg\/mL vs. 9.4\u00b19.7\u2009pg\/mL, respectively,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;0.001). FSH levels were lower in the transgender group treated with histrelin (0.8\u00b10.8 mIU\/mL vs. 1.9\u00b11.2 mIU\/mL in the leuprolide group,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      =0.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>GnRHa are effective in suppressing the HPG axis in transgender youth, similar to that observed in children with CPP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/trgh.2020.0007","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T12:55:27Z","timestamp":1593435327000},"page":"31-35","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Effectiveness of Puberty Suppression with Gonadotropin-Releasing Hormone Agonists in Transgender Youth"],"prefix":"10.1177","volume":"6","author":[{"given":"Juan Diego","family":"Mejia-Otero","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA."},{"name":"Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrin","family":"White","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"e_1_3_4_2_2","first-page":"1","article-title":"Use of gonadotropin-releasing hormone analogs in children: update by an International Consortium","author":"Bangalore Krishna K","year":"2019","unstructured":"Bangalore Krishna K, , John SF, , Alan DR, et al. Use of gonadotropin-releasing hormone analogs in children: update by an International Consortium. Horm Res Paediatr. 2019:1\u201316.","journal-title":"Horm Res Paediatr"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-1783"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-69-5-1087"},{"issue":"1","key":"e_1_3_4_5_2","first-page":"723","article-title":"Carel JC, Chaussain JL, et al","volume":"13","author":"Lahlou N","year":"2000","unstructured":"Lahlou N. Carel JC, Chaussain JL, et al. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000; 13 Suppl 1:723\u2013737.","journal-title":"Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/11204800-000000000-00000"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.17119"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3251"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000496115"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.01943.x"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-2958"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01658"},{"key":"e_1_3_4_13_2","unstructured":"FDA. Vantas prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021732s013lbl.pdf Last accessed on September20 2019."},{"key":"e_1_3_4_14_2","unstructured":"Abbvie. https:\/\/www.rxabbvie.com\/pdf\/lupron3_75mg.pdf Last accessed on September20 2019."}],"container-title":["Transgender Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/trgh.2020.0007","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/trgh.2020.0007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/trgh.2020.0007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:39:46Z","timestamp":1777588786000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/trgh.2020.0007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2,1]]}},"alternative-id":["10.1089\/trgh.2020.0007"],"URL":"https:\/\/doi.org\/10.1089\/trgh.2020.0007","relation":{},"ISSN":["2688-4887","2380-193X"],"issn-type":[{"value":"2688-4887","type":"print"},{"value":"2380-193X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}